Our study proposes the CRAFITY-100 RULE, which integrates baseline inflammatory and tumor markers (CRP, AFP, PIVKA-II) with their early kinetic changes, to better stratify patients with unresectable HCC undergoing immunotherapy. Here, CRP is linked to neoplasm.